G1 Therapeutics, Inc.

Trimeris, Inc.

Pharmacosmos Holding A/s

Mind Medicine, Inc.

Stephen E Schneider

Hannah S White

Jay Copeland Strum

Alexander Smith

Jaroslaw Mazurek

Brian L Bray

Huyi Zhang

Paul Erickson Friedrich

John Dwyer

Barbara E Johnston

Sagar Beldar

Thomas Fessard

Gerald S Jones

Peter Mack

Nicolai A Tvermoes

Jon Schroeder

Robert Barrow

Nikolai A Tvermores

Paul E Friedrich

An advantageous isolated morphic form of trilaciclib which is 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one, for example in the form of a dihydrochloride salt or a dihydrochloride, dihydrate.

Morphic forms of trilaciclib and methods of manufacture thereof

This invention provides a process for preparing 1,4-diazaspiro[5.5]undecan-3-one and analogues thereof that are useful in the preparation of pharmaceutical compound, including for the treatment of disorders involving abnormal cellular proliferation. Chemical intermediates in the process are also provided.

Synthesis of 1,4-diazaspiro[5.5]undecan-3-one

An advantageous isolated morphic form of trilaciclib which is 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.

A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual and treating the disease or condition.

Formulations of psilocin that have enhanced stability

An advantageous isolated morphic form of trilaciclib which is 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7&#x2032;,8&#x2032;-dihydro-6&#x2032;H-spiro[cyclohexane-1,9&#x2032;-pyrazino[1&#x2032;,2&#x2032;:1,5]pyrrolo[2,3-d]pyrimidin]-6&#x2032;-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.

Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or more of a pharmaceutically acceptable carrier and macromolecular carrier, and uses and methods of treatment provided by these compositions.

HIV fusion inhibitor peptides with improved biological properties

Growing community of inventors

Raleigh, NC, United States of America

Stephen E Schneider